The therapeutic potential of certain phytocannabinoids produced by the Cannabis sativa plant is now well-recognised and has been proven by the regulatory approval for medical use of cannabidiol (Epidiolex®), chemically synthesized delta-9-tetrahydrocannabinol (Marinol® and Syndros®) and 1:1 delta-9-tetrahydrocannabinol/cannabidiol (Sativex®).
In our latest publication, we have evaluated the growing evidence from non-clinical and clinical studies for the anti-inflammatory and antioxidant effects of phytocannabinoids, discussed their proposed mode of action' and assessed the potential of phytocannabinoids and their synthetic analogues to be efficacious treatments for neuroinflammatory disorders.
The paper was written by Sharon Smith and David Heal of DevelRx and Ruarri Spurgeon and Taurri Spurgeon of Medicanna and EthicaCBD. It was recently published as part of a Special Issue ‘Natural Products in Neurotherapeutic Applications’ (Editor: Marcello Iriti) in Exploration of Neuroprotective Therapy.
The full details of the review are:
Smith S, Spurgeon T, Spurgeon R, Heal D. Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation. Explor Neuroprot Ther. 2024;4:325–48. https://doi.org/10.37349/ent.2024.00087
You can read the full text of the article here
If you are developing novel therapies from cannabinoids and would like to find out more about our experience in this area and how we can assist you please get in touch.